Published in Chest on July 01, 2001
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56
Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax (2004) 3.77
Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther (2007) 2.65
Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis (2003) 1.93
Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome. Biomark Med (2008) 1.55
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) (2007) 1.49
Current concepts in the management of tuberculosis. Mayo Clin Proc (2011) 1.36
The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med (2012) 1.32
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother (2013) 1.27
Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev (2009) 1.21
Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART. Clin Dev Immunol (2010) 1.03
Co-infection with human immunodeficiency virus and tuberculosis in Asia. Tuberculosis (Edinb) (2007) 0.98
Peripartum tuberculosis as a form of immunorestitution disease. Eur J Clin Microbiol Infect Dis (2003) 0.94
Tuberculosis and HIV disease: two decades of a dual epidemic. Wien Klin Wochenschr (2003) 0.93
Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. Afr Health Sci (2008) 0.93
Predicting results of mycobacterial culture on sputum smear reversion after anti-tuberculous treatment: a case control study. BMC Infect Dis (2010) 0.92
Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. J Infect Dis (2014) 0.87
Immune reconstitution inflammatory syndrome in association with HIV/AIDS and tuberculosis: views over hidden possibilities. AIDS Res Ther (2007) 0.85
Women, immigration, poverty and tuberculosis. Multidiscip Respir Med (2010) 0.83
A case for treating high hepatitis B DNA levels before starting HIV therapy. AIDS (2006) 0.79
The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum. Curr Opin Infect Dis (2016) 0.78
Progressive neuropsychiatric problems following institution of highly active antiretroviral therapy. Sex Transm Infect (2005) 0.78
Tuberculosis-Associated Immune Reconstruction Inflammatory Syndrome (TB-IRIS) in HIV-Infected Patients: Report of Two Cases and the Literature Overview. Case Rep Infect Dis (2013) 0.77
Prolonged paradoxical reaction of tuberculosis in an HIV-infected patient after initiation of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis (2003) 0.75
Disseminated tuberculosis infection and paradoxical reaction during antimycobacterial treatment related to TNF-alpha blocker agent Infliximab. Respir Med Case Rep (2014) 0.75
Paradoxical response in spinal tuberculosis: Lessons learnt. J Neurosci Rural Pract (2016) 0.75
[Immune reconstitution syndrome]. Z Rheumatol (2012) 0.75
[Immune reconstitution inflammatory syndrome (IRIS)]. Z Rheumatol (2008) 0.75
Clinical and radiological deterioration in a patient with AIDS. Eur Radiol (2005) 0.75
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med (1993) 8.49
Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health (1987) 5.06
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med (1999) 5.05
Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis (2005) 4.36
Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis (1987) 4.11
Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med (1994) 4.04
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) (1988) 4.03
Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr (2001) 3.67
Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.64
Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol (1998) 3.62
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis (1992) 3.61
Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA (2001) 3.53
The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA (1996) 3.53
Routine prenatal screening for HIV infection. Lancet (1991) 3.43
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet (1998) 3.37
Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis (2013) 3.08
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nat Med (2000) 2.97
Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis (2006) 2.97
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med (1991) 2.77
Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS (1999) 2.73
A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1996) 2.70
Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses (2004) 2.64
Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother (1999) 2.54
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Errors in the treatment of tuberculosis in Baltimore. Chest (2000) 2.46
Projections of AIDS morbidity and mortality in San Francisco. JAMA (1990) 2.42
Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis (2005) 2.40
Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.29
Eleven years of community-based directly observed therapy for tuberculosis. JAMA (1995) 2.27
Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA (2000) 2.25
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis (1999) 2.18
Latent tuberculosis infection among undergraduate medical students in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis (2005) 2.16
Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med (1996) 2.14
Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med (1991) 2.12
Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. JAMA (1991) 2.08
Incidence of salmonellosis in patients with AIDS. J Infect Dis (1987) 2.04
Mycobacteria and AIDS mortality. Am Rev Respir Dis (1989) 2.02
Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis (1995) 2.01
New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis (2012) 1.97
Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis (1998) 1.97
Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis (2008) 1.94
Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis (2006) 1.91
Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.89
Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS (2001) 1.88
Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med (1994) 1.87
Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis (2011) 1.76
Multiple paralogous genes related to the Streptomyces coelicolor developmental regulatory gene whiB are present in Streptomyces and other actinomycetes. Microbiology (2000) 1.75
Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care (2007) 1.75
Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. Int J Tuberc Lung Dis (2011) 1.71
The Staphylococcus aureus rsbW (orf159) gene encodes an anti-sigma factor of SigB. J Bacteriol (1999) 1.71
Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF. Infect Immun (2000) 1.68
Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med (1991) 1.67
Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis (1990) 1.60
Epidemiologic usefulness of spoligotyping for secondary typing of Mycobacterium tuberculosis isolates with low copy numbers of IS6110. J Clin Microbiol (2001) 1.60
Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med (1995) 1.60
HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS (2001) 1.60
Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med (1996) 1.59
The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest (1998) 1.58
Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis (2012) 1.58
Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis (1996) 1.58
whmD is an essential mycobacterial gene required for proper septation and cell division. Proc Natl Acad Sci U S A (2000) 1.57
Molecular cloning and characterization of AqpZ, a water channel from Escherichia coli. J Biol Chem (1995) 1.56
Measurement of HIV risk behaviors among intravenous drug users. Br J Addict (1992) 1.53
The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest (1995) 1.53
Health effects and exposure assessment of aerosolized pentamidine handlers. Chest (1993) 1.52
A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis (2002) 1.51
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother (1991) 1.48
Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. J Infect Dis (1995) 1.45
Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun (2004) 1.44
Attenuation of virulence in Mycobacterium tuberculosis expressing a constitutively active iron repressor. Proc Natl Acad Sci U S A (1999) 1.43
Color selection with a hygromycin-resistance-based Escherichia coli-mycobacterial shuttle vector. Gene (1995) 1.42
Exposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistors. Antimicrob Agents Chemother (1999) 1.41
The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis (1998) 1.40
Sigma factors of Mycobacterium tuberculosis. Tuber Lung Dis (1997) 1.40
Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med (2000) 1.35
Mycobacterium tuberculosis sigF is part of a gene cluster with similarities to the Bacillus subtilis sigF and sigB operons. Tuber Lung Dis (1997) 1.33
Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS (1999) 1.33
Patient and health care system delays in pulmonary tuberculosis diagnosis in a low-incidence state. Int J Tuberc Lung Dis (2005) 1.33
TB treatment: as simple as DOT? Int J Tuberc Lung Dis (2003) 1.32
Conditional sigma factor expression, using the inducible acetamidase promoter, reveals that the Mycobacterium tuberculosis sigF gene modulates expression of the 16-kilodalton alpha-crystallin homologue. J Bacteriol (1999) 1.32
Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis (1988) 1.31
Transmission of Mycobacterium tuberculosis by a fiberoptic bronchoscope. Identification by DNA fingerprinting. JAMA (1997) 1.30
Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis (2008) 1.28
Transmission of Mycobacterium tuberculosis through casual contact with an infectious case. Arch Intern Med (2001) 1.28
HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis (2009) 1.27
Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol (1995) 1.24
Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis (2008) 1.23
Human immunodeficiency virus infection in women attending an inner-city prenatal clinic: ineffectiveness of targeted screening. Sex Transm Dis (1991) 1.23
Regulation of the Escherichia coli water channel gene aqpZ. Proc Natl Acad Sci U S A (1998) 1.22